Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CSF effects on frataxin expression in Friedreich ataxia
2017-003084-34Phase 2Completed
- Sponsor
- University of Bristol
- Start
- Nov 2017
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenograstim in Friedreich ataxia (FA), sponsored by University of Bristol. Primary endpoints: Frataxin gene expression in peripheral blood cells and Frataxin protein expression in peripheral blood cells. Started Nov 2017; status: completed.
02
Drugs
lenograstim
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on 2017-003084-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003084-34.